J
Jack
MENLO PARK, Calif.--(BUSINESS WIRE)--Sept. 24, 2004--Corazon Technologies Inc., developer of an innovative method for removing calcium from aortic valves, reported results from its initial human clinical trials. These data will be presented Thursday September 29th at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. Patients treated with the company's stopped-heart system benefited from improved aortic valve function with structural preservation. This improvement was tracked throughout the 6-month follow-up period. The study concluded that in-situ demineralization may be a safe and effective repair method for calcified, stenotic aortic valves. Larger studies are planned in order to determine the safety and effectiveness of the device.
The Corazon technology is anticipated to facilitate aortic valve replacement and improve outcomes, including implant durability. In addition, both applications are being incorporated into a beating heart platform. It is believed this beating heart platform will allow clinicians to perform valve repairs or enable valve replacements either percutaneously or surgically. The beating heart system is planned for clinical evaluation during the first half of 2005.
http://home.businesswire.com/portal...d=news_view&newsId=20040924005026&newsLang=en
http://www.corazon-inc.com/press_20040924.pdf
The Corazon technology is anticipated to facilitate aortic valve replacement and improve outcomes, including implant durability. In addition, both applications are being incorporated into a beating heart platform. It is believed this beating heart platform will allow clinicians to perform valve repairs or enable valve replacements either percutaneously or surgically. The beating heart system is planned for clinical evaluation during the first half of 2005.
http://home.businesswire.com/portal...d=news_view&newsId=20040924005026&newsLang=en
http://www.corazon-inc.com/press_20040924.pdf